How should I monitor repeat serum testosterone levels in a male patient using Androgel (testosterone gel)?

Monitoring Testosterone Levels in Patients on AndroGel

For patients on AndroGel (transdermal testosterone gel), check serum testosterone levels 3-6 months after starting treatment, then annually thereafter, with blood drawn at any time after the patient has been on treatment for at least 1 week. 1, 2

Timing of Initial Monitoring

The Endocrine Society guidelines are clear that transdermal gels have unique monitoring requirements compared to other testosterone formulations:

• First check: 3-6 months after initiation 1, 2
• Timing of blood draw: Any time after at least 1 week of treatment 1
• The 2018 updated guideline specifies 2-8 hours following gel application for optimal assessment 2

This differs significantly from injectable testosterone, which requires midpoint timing between injections, or patches, which require 3-12 hours post-application. The flexibility in timing for gels reflects their more stable pharmacokinetic profile 1.

Target Testosterone Range

Aim for mid-normal range testosterone levels (approximately 400-700 ng/dL). 1, 2

The guidelines consistently emphasize targeting the mid-normal range rather than supraphysiologic levels. If testosterone is >700 ng/dL or <400 ng/dL, adjust the dose 1. The FDA label for AndroGel confirms this approach, recommending dose adjustments based on whether levels fall below or exceed the normal range 3.

Dose Adjustment Protocol

Based on the initial testosterone level at 3-6 months:

• If testosterone is below normal range: Increase from 5g to 7.5g, or from 7.5g to 10g 3
• If testosterone exceeds normal range: Decrease the dose 3
• If testosterone consistently exceeds normal at 5g dose: Discontinue AndroGel 3

Ongoing Monitoring Schedule

After the initial 3-6 month check:

• Testosterone levels: Annually 1, 2
• Hematocrit: At 3-6 months, then annually 1, 2
• Clinical assessment: Annually to assess symptom response and adverse effects 1, 2

Critical Safety Monitoring

Beyond testosterone levels, concurrent monitoring is essential for patient safety:

Hematocrit monitoring is mandatory - Stop therapy if hematocrit exceeds 54%, evaluate for hypoxia and sleep apnea, then reinitiate at reduced dose once hematocrit normalizes 1, 2. This is particularly important as testosterone gel can cause dose-dependent erythrocytosis 4.

For men 40+ years (or 55-69 years per 2018 guidelines) who choose prostate monitoring: 2

• PSA and digital rectal exam at baseline
• Repeat at 3-12 months
• Then follow age-appropriate screening guidelines
• Obtain urology consultation if PSA increases >1.4 ng/mL within 12 months or confirmed PSA >4.0 ng/mL 1, 2

Common Pitfalls to Avoid

Don't check testosterone levels too early - Wait at least 1 week after starting gel for steady-state levels to be achieved 1. Checking earlier will give falsely low or variable results.

Don't forget formulation-specific counseling - Advise patients to cover application sites with clothing and wash hands after application to prevent transfer to others 1. This is a unique safety concern with gels not present with other formulations.

Don't rely solely on total testosterone in obese patients - Consider checking free testosterone by equilibrium dialysis, as obesity lowers sex hormone-binding globulin and can make total testosterone misleadingly low 5, 6.

Don't assume one-size-fits-all timing - While guidelines allow "any time" blood draws for gels after 1 week of use, the 2018 guideline's recommendation of 2-8 hours post-application may provide more consistent results 2.